883.1500 14.30 (1.65%)
NSE Apr 15, 2025 15:31 PM
Volume: 1.6M
 

Rudra Shares and Stock Brokers Ltd
Cadila Healthcare has emerged at the forefront of India's battle to fight against COVID-19. Company is one of the world's largest producer of anti-malarial drug hydroxychloroquine which is widely used as a prophylactic drug to prevent COVID-19 infections. Apart from that, to offer treatment options for COVID 19, company is now exploring multiple options from its portfolio of biological products and based on the available evidence, has selected the long-acting biological therapy, Pegylated Interferon alpha-2b as a potential treatment. It may be noted that Zydus Cadila has been commercially manufacturing Pegylated Interferon Alpha-2b under the...
Zydus Lifesciences L.. has an average target of 1089.17 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended